Sairy Hernandez

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 6.8K citations · Full text

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin et al. · The Lancet Oncology · 2021 · 362 citations

Patient-reported Outcomes, Hepatology, Medicine +11

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

Ann‐Lii Cheng, S. Qin, Masafumi Ikeda et al. · Annals of Oncology · 2019 · 191 citations

Ph Iii Study, Hepatology, Medicine +10

Survival for Women and Men with AIDS

George F. Lemp, A. Hirozawa, Judith B. Cohen et al. · The Journal of Infectious Diseases · 1992 · 125 citations

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Shukui Qin, Zhenggang Ren, Yin‐Hsun Feng et al. · Liver Cancer · 2021 · 123 citations · Full text